Vaccine Info

V920 Ebola

Merck's V920  (rVSVΔG-ZEBOV-GP)  investigational vaccine candidate to prevent the onset of Ebola Zaire, is a prime/boost candidate vaccine based on Ad26- and MVA-vectored components (Ad26.ZEBOV/MVA-BN-Filo) and the Ad5-EBOV candidate vaccine.

The vaccine is currently being studied in Phase 3 clinical trials.

This experimental vaccine (rVSV∆G-ZEBOV-GP) has been given to approximately 93,965 healthcare workers in the DRC.

Recent clinical trial: African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola 

Updated
April 20th, 2019